Vir Biotechnology, Inc.·4

Apr 7, 4:50 PM ET

De Backer Marianne 4

Research Summary

AI-generated summary

Updated

Vir Biotechnology (VIR) CEO Marianne De Backer Sells 72,559 Shares

What Happened Marianne De Backer, President, CEO and a director of Vir Biotechnology (VIR), disposed of 72,559 shares on 2026-04-06 at $9.16 per share for a total of $664,350. The transaction was a sale (S) and was executed to satisfy tax withholding obligations tied to the vesting of restricted stock units.

Key Details

  • Transaction date and price: 2026-04-06, 72,559 shares at $9.16/share.
  • Total proceeds: $664,350.
  • Shares owned after transaction: Not reported in the provided excerpt; see the full Form 4 for post-transaction holdings.
  • Footnotes: Sale was an automatic, mandatory sale under a Rule 10b5-1 arrangement to satisfy issuer tax withholding (not a discretionary trade) and the shares are held in the Ureel-De Backer Family Trust, of which the reporting person and her spouse are trustees.
  • Filing timeliness: Form filed 2026-04-07 for a 2026-04-06 transaction — appears to be timely (filed one day after the transaction).

Context This was an automatic sale to cover tax withholding on vested restricted stock units, not an ad hoc decision by the insider. Such tax-withholding sales are common and generally not viewed as a signal of the insider's view on the company's prospects. For full holdings, plan details, or additional related transactions, review the complete Form 4 filing (Accession: 0001628280-26-024098).